Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy: A Combined Population-based Analysis

Carlotta Palumbo, Angela Pecoraro, Sophie Knipper, Giuseppe Rosiello, Zhe Tian, Shahrokh F. Shariat, Claudio Simeone, Alberto Briganti, Fred Saad, Alfredo Berruti, Alessandro Antonelli, Pierre I. Karakiewicz

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan–Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated. Results: Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively. Conclusion: Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible.

Original languageEnglish
Pages (from-to)4357-4361
Number of pages5
JournalAnticancer Research
Volume39
Issue number8
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • Complication
  • Metastasectomy
  • Metastasis
  • Renal cell carcinoma
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survival and complication rates of metastasectomy in patients with metastatic renal cell carcinoma treated exclusively with targeted therapy: A Combined Population-based Analysis'. Together they form a unique fingerprint.

Cite this